"Lymphoproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
- Lymphoproliferative Disorders
- Disorder, Lymphoproliferative
- Disorders, Lymphoproliferative
- Lymphoproliferative Disorder
X-Linked Lymphoproliferative Disorder
- X-Linked Lymphoproliferative Disorder
- Disorder, X-Linked Lymphoproliferative
- Disorders, X-Linked Lymphoproliferative
- Lymphoproliferative Disorder, X-Linked
- Lymphoproliferative Disorders, X-Linked
- X Linked Lymphoproliferative Disorder
- X-Linked Lymphoproliferative Disorders
- Epstein-Barr Virus Infection, Familial Fatal
- Epstein Barr Virus Infection, Familial Fatal
- Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males
- Epstein Barr Virus Induced Lymphoproliferative Disease In Males
- Familial Fatal Epstein-Barr Infection
- Familial Fatal Epstein Barr Infection
- Immunodeficiency 5
- Immunodeficiency 5s
- Duncan's Syndrome
- Lymphoproliferative Disease, X-Linked
- Disease, X-Linked Lymphoproliferative
- Diseases, X-Linked Lymphoproliferative
- Lymphoproliferative Disease, X Linked
- Lymphoproliferative Diseases, X-Linked
- X-Linked Lymphoproliferative Diseases
- Lymphoproliferative Syndrome, X-Linked, 1
- Purtilo Syndrome
- Purtilo Syndromes
- Syndrome, Purtilo
- Syndromes, Purtilo
- X-Linked Lymphoproliferative Disease
- X Linked Lymphoproliferative Disease
- X-Linked Lymphoproliferative Syndrome
- Lymphoproliferative Syndrome, X-Linked
- Lymphoproliferative Syndromes, X-Linked
- Syndrome, X-Linked Lymphoproliferative
- Syndromes, X-Linked Lymphoproliferative
- X Linked Lymphoproliferative Syndrome
- X-Linked Lymphoproliferative Syndromes
- Duncan Disease
- Disease, Duncan
- Immunodeficiency, X-Linked Progressive Combined Variable
- Immunodeficiency, X Linked Progressive Combined Variable
Below are MeSH descriptors whose meaning is more general than "Lymphoproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Lymphoproliferative Disorders".
This graph shows the total number of publications written about "Lymphoproliferative Disorders" by people in this website by year, and whether "Lymphoproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoproliferative Disorders" by people in Profiles.
Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol. 2018 02; 70(2):298-307.
Hypopigmented interface T-cell dyscrasia: a form of cutaneous T-cell dyscrasia distinct from hypopigmented mycosis fungoides. J Dermatol. 2014 Jul; 41(7):609-17.
Lymphoproliferative disease of the central nervous system in a patient with dermatomyositis on immunomodulation therapy. Clin Neuropathol. 2013 Mar-Apr; 32(2):135-8.
Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant. 2012 Sep; 16(6):E201-9.
The role of Fas in the immune system biology of IL-2R alpha knockout mice: interplay among regulatory T cells, inflammation, hemopoiesis, and apoptosis. J Immunol. 2005 Aug 01; 175(3):1965-73.
The application of a monoclonal antibody to CD62L on paraffin-embedded tissue samples in the assessment of the cutaneous T-cell infiltrates. J Cutan Pathol. 2005 Jan; 32(1):12-20.
Pityriasis lichenoides: a clonal T-cell lymphoproliferative disorder. Hum Pathol. 2002 Aug; 33(8):788-95.
Lichenoid and granulomatous dermatitis. Int J Dermatol. 2000 Feb; 39(2):126-33.
Primary intraocular posttransplantation lymphoproliferative disorder. Arch Ophthalmol. 1998 Dec; 116(12):1667-9.